TOMI Unlocks UK Market with Advanced Disinfection Tech Approval

FREDERICK, MD – February 23, 2026 – TOMI Environmental Solutions, Inc. has secured a pivotal victory in its global expansion strategy, receiving official biocidal product authorizations from Great Britain's Health and Safety Executive (HSE). The approvals clear the way for the company’s SteraMist brand of disinfection equipment and its proprietary Binary Ionization Technology (BIT) solution to be marketed across Great Britain and Northern Ireland, unlocking significant access to the region's high-demand healthcare, pharmaceutical, and hospitality sectors.

This regulatory milestone, announced today, grants formal authorization for the company's hydrogen peroxide-based technology under two distinct post-Brexit frameworks. The BIT solution is now approved in Great Britain (England, Scotland, and Wales) under Regulation 528/2012 GB, and a separate, parallel approval was obtained for Northern Ireland, which continues to operate under the European Union’s Regulation (EU) No. 528/2012. For investors and industry analysts tracking the NASDAQ-listed company (TOMZ), this dual approval is seen as a critical de-risking event that validates the technology's efficacy and safety while creating immediate revenue opportunities.

Elissa J. Shane, Chief Operating Officer of TOMI, highlighted the strategic importance of the achievement. “This not only enhances our market footprint but also reinforces our commitment to providing innovative solutions that meet rigorous compliance, safety, and efficacy standards,” she stated. The approvals cover both room fogging and handheld direct spray applications, positioning SteraMist as a versatile tool for disinfecting a wide array of hard, non-porous surfaces in everything from hospital clean rooms to hotel suites.

A New Standard in Disinfection Technology

At the heart of TOMI's market proposition is its innovative Binary Ionization Technology (BIT) platform. Originally developed with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), the system uses a low-concentration hydrogen peroxide solution as its only active ingredient. This solution is passed through a high-energy cold plasma arc, which ionizes the peroxide, creating a fine fog or mist of what the company calls ionized Hydrogen Peroxide (iHP).

This iHP aerosol functions like a gas, reaching into nooks, crannies, and other hard-to-reach areas that traditional spray-and-wipe methods often miss. A key advantage highlighted by the company is its non-caustic nature and favorable environmental profile; after deactivating pathogens, iHP breaks down into harmless water and oxygen, leaving no toxic residues. This makes it particularly suitable for sensitive environments like pharmaceutical manufacturing labs, food processing facilities, and patient rooms where material compatibility and human safety are paramount.

The efficacy data submitted to and approved by the HSE is robust. The BIT solution demonstrated bactericidal, yeasticidal, and virucidal properties with contact times as short as five minutes for some applications. This rapid, broad-spectrum efficacy is a significant selling point in a market grappling with challenges like healthcare-associated infections (HAIs) and the rise of multi-drug resistant organisms (MDROs). While competing technologies like vaporized hydrogen peroxide (VHP) and UV-C light systems also offer automated, no-touch disinfection, TOMI's iHP technology aims to carve out its niche through its unique combination of rapid deployment, material compatibility, and proven performance.

Navigating the Complex Post-Brexit Regulatory Maze

Securing these approvals was no simple task, representing a successful navigation of the complex and bifurcated regulatory landscape in the United Kingdom following its departure from the European Union. Great Britain now operates its own biocidal products framework, the GB BPR, which mirrors its EU counterpart but is managed independently by the HSE. Companies must submit complete, independent dossiers to the British authority for market access.

Simultaneously, under the Northern Ireland Protocol, Northern Ireland remains aligned with the EU’s Biocidal Products Regulation (BPR). This required TOMI to pursue a separate authorization compliant with EU standards for that market. Successfully clearing both hurdles demonstrates a high level of regulatory diligence and provides the company with a powerful credential. Such certifications are essential for building trust among facility managers and public health officials, who rely on government-validated claims of safety and effectiveness.

The process for biocidal product approval in both the UK and EU is notoriously rigorous, demanding extensive data on a product's efficacy against a range of microorganisms, its toxicological profile for human health, and its environmental impact. This high barrier to entry effectively filters the market, ensuring that only products with strong scientific backing can be legally sold for disinfection purposes.

With the UK and NI approvals now in hand, all eyes are on the company's next objective: full EU-wide authorization. As COO Elissa J. Shane noted, “We are optimistic that our separate application under the EU Biocidal Products Regulation (BPR) for the European Union will also be approved this year, opening doors in additional countries across Europe.” Success in Great Britain is often seen as a strong positive indicator for a favorable outcome with the European Chemicals Agency (ECHA), which oversees the EU BPR. Achieving this would transform TOMI’s European presence from a foothold into a continent-spanning operation, granting access to one of the world's largest and most regulated disinfection markets.